Therapeutic Evaluation of STeroids in IgA Nephropathy Global study (TESTING)
Aim: The TESTING study will evaluate the long-term efficacy and safety of oral methylprednisolone compared to matching placebo on a background of routine RAS inhibitor therapy, in preventing kidney events in patients with IgA nephropathy and features suggesting a high risk of progression.
Method: A randomised, parallel-group, two-arm, long-term study utilising a placebo-controlled design study involving approximately 500 participants, from Australia, Canada, China, India and Malaysia who will be followed up for a mean of five years.
Status: 262 participants have been randomised to the original full-dose TESTING study. These participants continue to be followed up.
A further 240 participants will be randomised to the low-dose protocol. Recruitment has started at sites in Australia, Canada, China and India. Start-up activities are underway in Malaysia.